A call to solve the controversy on omega-3FAs trials - PACE-CME

A call to solve the controversy on omegaFAs trials

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Can targeting of IL-6 lead to CV protection in CKD?
Can targeting of IL-6 lead to CV protection in CKD?
ACC.21
Can targeting of IL-6 lead to CV protection in CKD?
- Paul Ridker, MD
Renal denervation as option for patients with hypertension despite medications
Renal denervation as option for patients with hypertension despite medications
ACC.21
Renal denervation as option for patients with hypertension despite medications
- Prof. Ajay Kirtane, MD
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
ACC.21
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
- Prof. Derek Chew
No definite difference for primary endpoint but proven safety with ARNI in MI patients
No definite difference for primary endpoint but proven safety with ARNI in MI patients
ACC.21
No definite difference for primary endpoint but proven safety with ARNI in MI patients
- Prof. Marc Pfeffer, MD, PhD